BioCentury | Mar 12, 2020
Product Development

Targeted degradation gets another bump with Kymera’s $102M raise

It’s a big year for targeted protein degraders, and Kymera is adding to the momentum with a $102 million series C round that should bring its first three programs into the clinic. Biotechnology Value Fund...
BC Extra | Oct 23, 2019
Clinical News

Arvinas clears key hurdle, showing PROTACs orally bioavailable in clinic

Putting to rest concerns regarding oral bioavailability, Arvinas showed that its first two proteolysis-targeting chimeras achieved serum levels predicted to be efficacious. Wednesday’s presentation of Phase I data of ARV-110 for metastatic castration-resistant prostate cancer...
BioCentury | Jul 3, 2019
Emerging Company Profile

Kymera: a systematic approach to protein degradation

With a computational drug discovery platform and a proprietary library of E3 ligases and binders, Kymera believes it can accelerate the discovery and development of protein degraders. Protein degradation is entering the mainstream as a...
BC Innovations | Apr 11, 2019
Emerging Company Profile

Nurix: Two sides of protein degradation

Nurix is flipping the concept of targeted protein degradation on its head. In addition to the usual approach of inducing target destruction, the company has technology that can block E3 ligase activity and increase a...
BioCentury | Dec 1, 2018
Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
BC Innovations | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
BC Innovations | Dec 8, 2017
Targets & Mechanisms

Pathways emerging from ASH

A survey of the emerging molecular targets at this year’s American Society of Hematology conference indicates that while harnessing the immune system to treat cancer remains a dominant interest, processes for tuning protein levels --...
BC Innovations | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
BC Innovations | Oct 5, 2017
Product R&D

Nimble move

Celgene Corp. ’s deal with Nimbus Therapeutics LLC is another vote of confidence that Nimbus’ computational drug design technology can solve druggability problems that trip up standard medicinal chemistry. The partnership gives Celgene access to...
BC Innovations | May 11, 2017
Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
Items per page:
1 - 10 of 41